Breast Cancer

Natera announced the DARE trial examining Palbociclib to treat patients with advanced breast cancer will use its Signatera molecular residual disease test.

A study published in The BMJ concluded that a single dose of targeted radiotherapy was just as effective as conventional radiotherapy for women with early breast cancer.

The trial did not meet its primary end point of improved invasive disease-free survival in women with hormone receptor-positive HER2-negative early breast cancer who have residual invasive disease after completing neoadjuvant chemotherapy.

Findings from the phase 2 FLIPPER trial indicated that frontline fulvestrant (Faslodex) in combination with palbociclib (Ibrance) demonstrated an improvement in PFS at 1 year in patients with endocrine-sensitive HR-positive, HER2-negative metastatic breast cancer.

Results from the study suggest that ctDNA testing can be seen as a standard of care test for both common and rare genetic events for patients with breast cancer.

The collective study findings suggested that for risk assessment, the recurrence score needs to be complemented by clinicopathologic parameters for therapy decision making.

The agency indicated that the use of atezolizumab (Tecentriq) and paclitaxel in patients with previously untreated, inoperable, locally advanced, or metastatic triple negative breast cancer was not effective in treating the disease.

Researchers indicated that these findings highlight the need for clinicians to emphasize the importance of both smoking cessation and cancer screening for women who currently smoke.

The new drug application was based on data from a single, pivotal, randomized, controlled, phase 3 study of encequidar for the treatment of metastatic breast cancer.

Researchers from Singapore discussed their own experiences and strategies used to safely manage breast cancer during the COVID-19 pandemic.

A study published in Cancer found that the introduction of generic aromatase inhibitors reduced the decrease trend of adherence to hormonal therapy for patients with breast cancer.

Researchers suggested that these findings support a change of the current screening guidelines for this specific risk group and support MRI screening.

Researchers indicated that these study findings could set a basis to pinpoint independent prognostic factors related to a treatment modality in patients with breast cancer and provide clarity for the assessment of surrogate markers for overall survival.

A survey of breast cancer survivors in the US showed that “patients were universally affected by COVID in terms of delays in breast cancer care.”

According to researchers, mindfulness-based intervention may have a positive effect on subjective measures of cognitive impairment in breast cancer survivors.

Researchers indicated that especially among women considered to be midlife, metastatic breast cancer creates a high economic burden through lost productivity.

A study published in JAMA Network Open found that women who were diagnosed with interval breast cancers within 1 year of a negative mammogram result experienced worse survival rates than patients with breast cancer detected by screenings.

Though the results still need to be confirmed, researchers suggested these findings indicate a need to better understand how BMI affects the biology, progression, and treatment efficacy of breast cancer.

Researchers found that breast cancer survivors who were prescribed adjuvant endocrine therapy and regularly performed moderate physical activity reported better health-related quality-of-life.

Researchers suggested that these findings support using minimal residual disease as a major stratification variable in all clinical trials to be conducted in patients with triple negative breast cancer.

These study results suggested that a longer time to surgery does not lower overall survival for women with early-stage breast cancer who had to delay operations due to the COVID-19 pandemic.

The study evaluating atezolizumab in combination with paclitaxel compared to placebo plus paclitaxel did not meet its primary end point of progression-free survival in patients with metastatic triple-negative breast cancer.

Researchers specifically suggested that the 86-SNV score could be incorporated into breast cancer risk prediction models for patients carrying a pathogenic variant in BRCA1, BRCA2, and CHEK2.

Marking the first US applications for pembrolizumab in breast cancer, the applications are based on data from the KEYNOTE-355 and KEYNOTE-522 trials, respectively.

A Yale study found that states with expanded Medicaid diagnosed women with breast cancer at an earlier stage of disease and was associated with a reduced number of uninsured patients when compared to non-Medicaid expansion states.